logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5662.produswest2
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5662.produswest2
Showing 1 - 12 of 12 Items
Showing 1 - 12 of 12 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Review

The effectiveness of isoniazid preventive treatment among contacts of multidrug-resistant tuberculosis: A systematic review and individual-participant meta-analysis

Martinez L, Campbell JI, Linde L, Boulahbal F, Cayla JA,  et al.
2025-09-23 • American Journal of Respiratory and Critical Care Medicine
2025-09-23 • American Journal of Respiratory and Critical Care Medicine

RATIONALE

Recent empirical research suggests isoniazid may lead to a risk reduction ...

Journal Article
|
Research
Journal Article
|
Commentary
Journal Article
|
Letter

Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?

Bastard M, Bonnet MMB, du Cros PAK, Khamraev AK, 
Journal Article
|
Commentary

Reply from the Authors of Eligibility for the Shorter MDR-TB Regimen: Ambiguities in the WHO Recommendations

Varaine FFV, Guglielmetti L, Mitnick CD
2017-07-17 • American Journal of Respiratory and Critical Care Medicine
2017-07-17 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|
Letter
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Letter

Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant MDR-TB: How Much Better Are They?

Bastard M, Guglielmetti L, Huerga H, Hayrapetyan A, Khachatryan N,  et al.
2018-07-03 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|
Commentary

Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria

Varaine FFV, Guglielmetti L, Mitnick CD
2017-12-01 • American Journal of Respiratory and Critical Care Medicine
2017-12-01 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|
Review
Journal Article
|
Research

Effectiveness of bedaquiline use beyond six months in patients with multidrug-resistant tuberculosis

Trevisi L, Hernán MA, Mitnick CD, Khan UT, Seung KJ,  et al.
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform ...

Technical innovation in critical care in a world of constraints: lessons from the COVID-19 pandemic

Mekontso Dessap A, Richard JCM, Baker T, Godard A, Carteaux G
2023-01-30 • American Journal of Respiratory and Critical Care Medicine
2023-01-30 • American Journal of Respiratory and Critical Care Medicine
Hayrapetyan A, 
et al.
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
2015-02-01 • American Journal of Respiratory and Critical Care Medicine

Eligibility for the shorter multidrug-resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations

Varaine FFV, Guglielmetti L, Huerga H, Bonnet MMB, Kiria N,  et al.
2016-10-15 • American Journal of Respiratory and Critical Care Medicine
2016-10-15 • American Journal of Respiratory and Critical Care Medicine

Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection

Rangaka MX, Wilkinson KA, Seldon R, van Cutsem G, Meintjes GA,  et al.
2007-12-07 • American Journal of Respiratory and Critical Care Medicine
2007-12-07 • American Journal of Respiratory and Critical Care Medicine
RATIONALE: Two forms of the IFN-gamma release assay (IFNGRA) to detect tuberculosis infection are available, but neither has been evaluated in comparable HIV-infected and uninfected pers...

Culture conversion in patients treated with bedaquiline and/or delamanid. A prospective multicountry study

Franke MF, Khan P, Hewison C, Khan U, Huerga H,  et al.
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, so...
2018-07-03 • American Journal of Respiratory and Critical Care Medicine

New and repurposed drugs for pediatric multidrug-resistant tuberculosis. Practice-based recommendations

Harausz EP, Garcia-Prats AJ, Seddon JA, Schaaf HS, Hesseling AC,  et al.
2016-11-17 • American Journal of Respiratory and Critical Care Medicine
2016-11-17 • American Journal of Respiratory and Critical Care Medicine
It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and r...

Culture conversion in patients treated with bedaquiline and/or delamanid: A prospective multi-country study

Franke MF, Khan PY, Hewison CCH, Khan UT, Huerga H,  et al.
2020-07-24 • American Journal of Respiratory and Critical Care Medicine
2020-07-24 • American Journal of Respiratory and Critical Care Medicine
BACKGROUND
Bedaquiline and delamanid offer the possibility of more effective and less toxic multidrug-resistant tuberculosis (MDR-TB) treatment. With this treatment, however, some pa...